210631-20-2

Upstream product

• 127528-38-5 benzyl-2-acetamino-2-deoxy-4,6-O-isopropylidene-3-O-methoxycarbonylmethyl-α-D-glucopyranoside 
• 210631-18-8 (R)-4-{(S)-2-[2-((4aR,6S,7R,8R,8aS)-7-Acetylamino-6-benzyloxy-2,2-dimethyl-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yloxy)-acetylamino]-butyrylamino}-4-carbamoyl-butyric acid benzyl ester 
• 78604-09-8 2-(((4aR,6S,7R,8R,8aS)-7-acetamido-6-(benzyloxy)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy)acetic acid 
• 57-11-4 stearic acid 
• 210631-19-9 (R)-4-{(S)-2-[2-((2S,3R,4R,5S,6R)-3-Acetylamino-2-benzyloxy-5-hydroxy-6-hydroxymethyl-tetrahydro-pyran-4-yloxy)-acetylamino]-butyrylamino}-4-carbamoyl-butyric acid benzyl ester 

Relevant academic research and scientific papers

Synthesis and immunomodulating activity of lipophilic analogs of N-acetylnormuramoyl-L-2-aminobutanoyl-D-isoglutamine

N-Acetylnormuramoyl-L-2-aminobutanoyl-D-isoglutamine (7) and its lipophilic 6-O-octadecanoyl (8) and 6-O-(2-tetradecylhexadecanoyl) (9) derivatives were prepared and their immunoadjuvant activity and pyrogenicity were tested. Compounds 8 and 9 are less pyrogenic than muramoyl-dipeptide (MDP) and norMDP analog 7. Both lipophilic derivatives 8 and 9 are better adjuvants than MDP in cell mediated immunity.